Cancer Genetics
Develops and commercializes proprietary genomic tests and services to improve and personalize the diagnosis, prognosis, and response to treatment (theranosis) of cancer. Its proprietary tests target cancers that are difficult to prognose and predict treatment outcomes by using currently available mainstream techniques. These cancers include hematological, urogenital and HPV-associated cancers.
2012 STATISTICS
3-year growth:80%
2011 Revenue:$3 million
2008 Revenue:$1.7 million
Employees:45
#93
Top 100 New Jersey Companies
